Gilead Sciences reported positive Phase 3 results for Trodelvy in combination with Keytruda in first-line PD-L1+ metastatic ...
Gilead Sciences (NASDAQ:GILD) and Danish pharmaceutical company LEO Pharma on Saturday announced an agreement worth up to $1.7B to jointly develop and commercialize LEO’s anti-inflammatory drugs. As ...
Zacks Investment Research on MSN
Gilead Sciences (GILD) advances while market declines: Some information for investors
In the latest close session, Gilead Sciences (GILD) was up +1.72% at $141.95. This move outpaced the S&P 500's daily loss of 0.43%. Meanwhile, the Dow experienced a drop of 0.37%, and the ...
Gilead Sciences recently reported in The New England Journal of Medicine that its Phase 3 ASCENT-04/KEYNOTE-D19 trial showed Trodelvy plus Keytruda improved progression-free survival over Keytruda ...
Gilead Sciences Inc. reached an all-time high with its stock price hitting 141.74 USD. This milestone comes amidst a remarkable 1-year total return of 47.96%, according to Investi ...
Gilead Sciences advances global biopharmaceutical research as part of broader healthcare activity linked to the nasdaq 100 ...
US biotech Gilead Sciences today announced that its Trodelvy (sacituzumab govitecan-hziy) has now been added to the National ...
Gilead's Q3 results exceeded expectations, with EPS of $2.47 and revenue of $7.8 billion, driven by HIV franchise outperformance. Learn more about GILD stock here.
HIV/AIDS activists heralded the approval of a new twice-yearly pre-exposure prophylaxis (PrEP) medication last year, but ...
Swedish biotech Sprint Bioscience is selling off an early-stage TREX1 cancer program to Gilead Sciences for $14 million upfront, plus the chance to net up to $400 million in biobucks. Last year, ...
1mon
Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors despite daily gains
Shares of Gilead Sciences Inc. GILD advanced 1.90% to $124.07 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 0.53% to 6,926 ...
Needham upgraded Gilead stock to buy today. The analyst sees billion-dollar potential in Gilead's Yeztugo drug for preventing HIV. Gilead stock looked cheap before the upgrade. It could be an even ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results